---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-25-000028"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:56:28.324188+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment

## Summary
- Earnings release and call postponed; 10-K filing delayed until March 18, 2025.
- Preliminary FY2024 revenue near midpoint of $255M-$265M guidance.
- Additional time needed for goodwill impairment assessment related to Alphazyme LLC acquisition.
- Revenue recognition error for ~$3.9M shipment recorded in wrong quarter; no full-year impact.
- Assessing effectiveness of internal controls; material weakness in revenue recognition identified.

## SEC filing metadata
- accession: 0001823239-25-000028
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000028/0001823239-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000028/mrvi-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-25-000028
- JSON: https://secwatch.observer/filing/0001823239-25-000028.json
- Plain text: https://secwatch.observer/filing/0001823239-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.